New Delhi, India: Zydus Cadila, a pharmaceutical company, announced on Tuesday that it has gotten conditional approval from the US Food and Drug Administration to market Lenalidomide Capsules, which are used to treat certain types of malignancies.
The US Food and Drug Administration (USFDA) has given the company provisional approval to market Lenalidomide Capsules in the strengths of 2.5 mg, 5 mg, 10 mg, 15 mg, 20 mg, and 25 mg.
Lenalidomide is used to treat various types of cancers. It works by slowing or stopping the growth of cancer cells. It is also used to treat anemia in patients with certain blood/bone marrow disorders (myelodysplastic syndromes-MDS).
The drug will be manufactured at the group’s formulation manufacturing facility at the SEZ, Ahmedabad, the company said in a statement.